Ivonescimab before and after surgery for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new immunotherapy drug (ivonescimab) given before and after surgery, sometimes with chemotherapy, for people with operable non-small cell lung cancer. The goal is to see if it helps shrink tumors and keeps them from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your daily activity level is good (0 or 1 on a standard scale).
- You have non-small cell lung cancer that can be removed with surgery (stage II to IIIB T3N2).
- You have not received any previous cancer treatment for this lung cancer.
- Your tumor does not have an EGFR mutation or ALK gene change.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a new drug called Ivonescimab can improve outcomes when given before surgery for non-small cell lung cancer. It may help shrink tumors and make them easier to remove.
This study tests whether adding a new immunotherapy drug (ivonescimab or penpulimab) to standard chemotherapy before surgery helps people with early-stage lung cancer. It's for people whose cancer can be surgically removed and who haven't had treatment yet.
This trial tests whether two immunotherapy drugs (nivolumab and ipilimumab) given before surgery can help treat non-small cell lung cancer that is stage II to IIIA. It's for people whose tumors are removable and who haven't had prior cancer treatment.
This study tests a new immunotherapy drug called ivonescimab given before surgery for people with advanced head and neck cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
This trial tests an immunotherapy drug for people with stage 3 lung cancer that hasn't been treated yet. It's for those whose tumors don't have certain genetic changes and who have not had prior cancer treatment.
This trial tests a new immunotherapy drug (ivonescimab, also called AK112) combined with chemotherapy before surgery for people with esophageal squamous cell cancer that can be completely removed. The goal is to see if adding immunotherapy before surgery helps shrink the tumor and improve outcomes.
Hear when a new Perioperative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.